IMPL · Impel Pharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $12.65M | $668.0K |
| Cost of Revenue | $6.50M | $691.0K |
| Gross Profit | $6.16M | $23.0K |
| R&D | $11.46M | $28.30M |
| SG&A | $77.89M | $17.04M |
| Total Operating Expenses | $89.34M | $45.33M |
| D&A | $1.20M | $1.08M |
| Operating Income | ($83.18M) | ($45.33M) |
| Interest Expense | - | - |
| Income Tax | $0 | $1.0K |
| Net Income | ($106.31M) | ($45.80M) |
| EPS - Basic | ($5.25) | - |
| EPS - Diluted | ($4.53) | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Cash & Equivalents | $60.65M | $88.21M |
| Accounts Receivable | $7.44M | $1.35M |
| Inventory | $8.43M | $0 |
| Accounts Payable | $6.09M | $6.37M |
| Current Assets | $79.81M | $94.58M |
| Total Assets | $88.55M | $97.91M |
| Current Liabilities | $22.16M | $15.95M |
| Long-term Debt | $48.07M | $29.45M |
| Total Liabilities | $132.71M | $45.40M |
| Stockholders' Equity | ($44.16M) | $52.51M |
| Retained Earnings | ($321.11M) | ($214.80M) |
Cash Flow
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Operating Cash Flow | ($93.64M) | ($39.18M) |
| Investing Cash Flow | ($1.38M) | ($1.78M) |
| Financing Cash Flow | $67.46M | $11.06M |
| CapEx | $1.38M | $1.78M |
| Free Cash Flow | ($95.02M) | ($40.97M) |
Ratios
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Profitability | ||
| Gross margin | 48.7% | 3.4% |
| Operating margin | -657.5% | -6786.5% |
| EBITDA margin | -648.0% | -6625.3% |
| Net margin | -840.3% | -6856.0% |
| Free cash flow margin | -751.0% | -6132.5% |
| FCF / Net income | 0.89 | 0.89 |
| R&D / Revenue | 90.5% | 4236.2% |
| SG&A / Revenue | 615.6% | 2550.3% |
| Effective tax rate | - | - |
| Return on assets | -120.1% | -46.8% |
| Return on equity | 240.8% | -87.2% |
| Return on invested capital | -1678.6% | -43.7% |
| Liquidity | ||
| Current ratio | 3.60 | 5.93 |
| Quick ratio | 3.22 | 5.93 |
| Cash ratio | 2.74 | 5.53 |
| Leverage | ||
| Debt / Equity | -1.09 | 0.56 |
| Debt / Assets | 0.54 | 0.30 |
| Debt / EBITDA | - | - |
| Interest coverage | - | - |
| Equity multiplier | -2.01 | 1.86 |
| Liabilities / Assets | 1.50 | 0.46 |
| Efficiency | ||
| Asset turnover | 0.14 | 0.01 |
| Inventory turnover | 0.77 | - |
| Days sales outstanding | 215d | 739d |
| Days inventory outstanding | 474d | 0d |
| Days payable outstanding | 342d | 3363d |
| Cash conversion cycle | 346d | -2624d |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | 1794.0% | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | 26669.6% | - |
| Operating income growth (YoY) | -83.5% | - |
| Net income growth (YoY) | -132.1% | - |
| EPS growth (YoY) | - | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | -132.0% | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2022-03-17.
Geographic
$150.00M totalUS$150.00M · 100.0%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-5.52
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing IMPEL PHARMACEUTICALS INC against the 5 most active filers in the same SIC group.